Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03331562
Recruitment Status : Completed
First Posted : November 6, 2017
Last Update Posted : October 8, 2020
Stand Up To Cancer
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
Translational Genomics Research Institute

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Completed
Actual Primary Completion Date : June 29, 2020
Actual Study Completion Date : July 10, 2020
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 November 9, 2021
December 7, 2021 Submission with QC Comments